The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Open accessAbstract
BACKGROUND: As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS: We conducted a phase 3, open-label study involving both previously treated and previously untreated patients infected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcotte class B). Patients were randomly assigned in a 1:1:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once daily for 12 weeks, sofosbuvir-velpatasvir plus ribavirin for 12 weeks, or sofosbuvir-velpatasvir for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Of the 267 patients who received treatment, 78% had HCV genotype 1, 4% genotype 2, 15% genotype 3, 3% genotype 4, and less than 1% genotype 6; no patients had genotype 5. Overall rates of sustained virologic response were 83% (95% confidence interval [CI], 74 to 90) among patients who received 12 weeks of sofosbuvir-velpatasvir, 94% (95% CI, 87 to 98) among those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 86% (95% CI, 77 to 92) among those who received 24 weeks of sofosbuvir-velpatasvir. Post hoc analysis did not detect any significant differences in rates of sustained virologic response among the three study groups. Serious adverse events occurred in 19% of patients who received 12 weeks of sofosbuvir-velpatasvir, 16% of those who received 12 weeks of sofosbuvir-velpatasvir plus ribavirin, and 18% of those who received 24 weeks of sofosbuvir-velpatasvir. The most common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and anemia (31%) in the patients receiving ribavirin. CONCLUSIONS: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. (Funded by Gilead Sciences; ASTRAL-4 ClinicalTrials.gov number, NCT02201901.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
Self-citationDavis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846
Self-citationCharlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., Fried, M. W., Terrault, N. A., O'Leary, J. G., Vargas, H. E., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.010 · Cited by 802
Self-citationForns, X., Charlton, M., Denning, J., McHutchison, J. G., Symonds, W. T., Brainard, D. M., Brandt-Sarif, T. S., Chang, P., Kivett, V. A., Castells, L., et al. (2014) · Hepatology · doi:10.1002/hep.27681 · Cited by 230
Self-citationDeterding, K., zu Siederdissen, C. H., Port, K., Solbach, P., Sollik, L., Kirschner, J., Mix, C., Cornberg, J., Worzala, D., Mix, H., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13343 · Cited by 121
Everson, G. T., Towner, W. J., Davis, M. N., Wyles, D. L., Nahass, R., Thuluvath, P. J., Etzkorn, K., Hinestrosa, F., Tong, M. J., Rabinovitz, M., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-1000 · Cited by 111
Self-citationSaxena, V., Nyberg, L. M., Pauly, M. P., Dasgupta, A., Nyberg, A. H., Piasecki, B. A., Winston, B. J., Redd, J. L., Ready, J. B., & Terrault, N. A. (2015) · Hepatology · doi:10.1002/hep.27922 · Cited by 110
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Dyson, J. K., Hutchinson, J., Harrison, L. E. A., Rotimi, O., TINIAKOS, D. G., Foster, G. R., Aldersley, M. A., & McPherson, S. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.041 · Cited by 96
Poordad, F. F., Schiff, E. R., Vierling, J. M., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30154-9 · Cited by 94
Self-citation
Cited by
Belli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251
Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients
Levitsky, J., Goldberg, D., Smith, A. R., Mansfield, S. A., Gillespie, B. W., Merion, R. M., Lok, A. S. F., Levy, G., Kulik, L., Abecassis, M., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.035 · Cited by 236
Watanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Kojima, Y., Tsuchiya, A., Ogawa, M., Nojiri, S., Takeuchi, S., Watanabe, T., Nakajima, K., Hara, Y., Yamashita, J., Kikuta, J., et al. (2019) · Regenerative Therapy · doi:10.1016/j.reth.2019.08.005 · Cited by 43
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C
Hoofnagle, J. H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.007 · Cited by 31
Metadata
- Authors
- Curry, M. P., O’Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., Reddy, K. R., Lawitz, E., Flamm, S. L., Schiano, T., Teperman, L., Fontana, R., Schiff, E., Fried, M., Doehle, B., An, D., McNally, J., Osinusi, A., Brainard, D. M., McHutchison, J. G., Brown, R. S., & Charlton, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-31
- Volume
- 373
- Issue
- 27
- Pages
- 2618-2628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2266909385
- Cited by
- 804
- References
- 11
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. https://app.cochat.ai/papers/10.1056/nejmoa1512614
- The paper
- Curry, M. P., O’Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., Reddy, K. R., Lawitz, E., Flamm, S. L., Schiano, T., Teperman, L., Fontana, R., Schiff, E., Fried, M., Doehle, B., An, D., McNally, J., Osinusi, A., Brainard, D. M., . . . Charlton, M. (2015). Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1512614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
